Pay in 4 interest-free payments of $6.42 Learn more
Ships within 48 hours · Estimated delivery Oct 5 - Oct 10
Best For: Patients who require advanced dual-action intervention for broader metabolic management
Cardiotoxicity Two small RCTs: Conflicting results, one showed no effect, one showed reduced cardiac events
August 12 Product: Ascendis Pharmas Yorvipath Indication: Hypoparathyroidism After a long regulatory road, Ascendis Pharma received FDA approval Monday for Yorvipath (TransCon PTH) for the treatment of hypoparathyroidism, a rare endocrine disease characterized by abnormally low levels of the parathyroid hormone
Consult a local physician to see if compounded semaglutide is right for you
US$ 23.18
US$ 24.51
US$ 21.11
US$ 28.17
US$ 28.36
US$ 26.34
